TGFB1 and renal cell carcinoma: These networks position m6A machinery as master regulators amenable to three strategic interventions: (1) Pathway-targeted inhibition (e.g., TGF-β/PI3K antagonists), (2) Context-specific regulator modulation (METTL3 inhibition in RCC vs activation in AKI recovery), and (3) Combined epitranscriptomic-metabolic targeting (dual METTL3/glycolytic enzyme inhibition in cystic diseases).